A Phase 3 interventional study of voriconazole in Candidiasis, sponsored by Pfizer. Terminated at 14 sites in 8 countries. Open to participants aged 2 Years to 17 Years. Per ClinicalTrials.gov, last updated 2016-06-23.
Sponsored by Pfizer · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 15 studies in Candidiasis by Pfizer — none open to participants now, none under way, none of them phase 3. Candidiasis · Pfizer.
Among the 15 studies in Candidiasis by Pfizer, this one is the 8th largest by enrollment of the 11 interventional ones that give a count, is the only one that started in 2010, is one of 6 in phase 3, and was the 13th registered.
132 studies on the registry are indexed under Candidiasis; 9 are open to participants now.
Browse Candidiasis studies →None of the 15 studies in Candidiasis by Pfizer is open now. The open studies under Candidiasis, anywhere →
Of the 6 Candidiasis studies recruiting now, 4 set no upper age limit and 2 stop at 75 or younger; 2 take children under 18; 3 take healthy volunteers.
This study: 2 Years to 17 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
15 studies; the count open now beside each. This study's row is marked.
First in 1998; this study’s year is marked. 1 started in 2010.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 23 is below the median of 91 across 86 interventional studies indexed under Candidiasis.
Median enrollment 41 across the 11 interventional studies, 526 across the 2 observational. Of the 15 that completed or were terminated, 7 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 15 studies in Candidiasis by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to determine whether voriconazole is safe and effective for the treatment of serious Candida infection and Candida infection of the esophagus in children and adolescents.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Creatinine clearance (CrCl)
How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
All subjects in this study will receive active voriconazole in an open-label fashion; there is no comparator in this study.
Drug: voriconazole
Subjects 12 - \<18 yrs (excluding subjects 12 - 14 yrs weighing \<50kg): For IC, the loading dose is 6 mg/kg IV q12h on Day 1, followed by 4 mg/kg IV q12h thereafter. Oral therapy, if given, will be administered at a dose of 200 mg q12h. For EC, no loading dose is required, and subjects will be initiated on 3 mg/kg IV q12h. Oral therapy, if given, will be administered at a dose of 200 mg q12h. Subjects 2 - \<12 yrs, and subjects 12 - 14 weighing \<50kg: For IC, the loading dose is 9 mg/kg IV q12h on Day 1, followed by 8 mg/kg IV q12h thereafter. For EC, no loading dose is required, and subjects will be initiated on 4 mg/kg IV q12. Oral therapy, if given, will be administered at a dose of 9 mg/kg q12h (maximum initial dose of 300 mg). Subjects will be treated for a minimum of 14 days for invasive candidiasis/candidemia or a minimum of 7 days for esophageal candidiasis. Subjects will be treated for up to a maximum of 42 days.
Also known as: Vfend
Percentage of Participants With Adverse Events - Overall Summary
Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, who discontinued due to AEs, or who had dose redued or temporarily discontinued due to AEs.
Time frame: Baseline up to 1 month follow-up
Percentage of Participants With a Global Response of Success at End of Treatment (EOT)
Global response was determined programmatically based on investigator assessment of clinical and microbiological response. Global response of success was defined as clinical cure or improvement AND microbiological eradication or presumed eradication. Exact 95 percent (%) confidence interval for binomial proportions using Clopper-Pearson method.
Time frame: EOT (from 7 to 42 days of treatment)
All-Cause Mortality - Number of Participant Deaths
Time frame: Day 28 and 1 Month Follow-up
Time to Death
Time frame: Baseline up to 1 month follow-up
| Milestone | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Started | 14 | 8 |
| Completed | 13 | 8 |
| Not completed | 1 | 0 |
| Withdrew: Other | 1 | 0 |
Percentage of participants with adverse events (AEs), serious adverse events (SAEs), severe AEs, who discontinued due to AEs, or who had dose redued or temporarily discontinued due to AEs.
| percentage of participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| With AEs | 92.9 | 75.0 |
| With SAEs | 14.3 | 12.5 |
| With severe AEs | 28.6 | 37.5 |
| Discontinued due to AEs | 14.3 | 25.0 |
| Dose reduced/temporary discontinuation due to AE | 21.4 | 0 |
Global response was determined programmatically based on investigator assessment of clinical and microbiological response. Global response of success was defined as clinical cure or improvement AND microbiological eradication or presumed eradication. Exact 95 percent (%) confidence interval for binomial proportions using Clopper-Pearson method.
| percentage of participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Percentage of Participants With a Global Response of Success at End of Treatment (EOT) | 88.9 (51.75 to 99.72) | 62.5 (24.49 to 91.48) |
| participants | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Day 28 | 0 | 0 |
| 1 Month Follow-up | 0 | 0 |
No measurements were reported for this outcome.
Collected over Day 1 up to Day 49 (7 days after the last dose of study drug). Non-serious events are listed at a 2% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Voriconazole: 2 to <12 Years | — | 2/14 (14.3%) | 13/14 (92.9%) |
| Voriconazole: 12 to <18 Years | — | 1/8 (12.5%) | 6/8 (75%) |
| Event | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| Splenic candidiasisInfections and infestations | 0/14 | 1/8 |
| Febrile neutropeniaBlood and lymphatic system disorders | 1/14 | 0/8 |
| PneumoniaInfections and infestations | 1/14 | 0/8 |
| Event | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years |
|---|---|---|
| OesophagitisGastrointestinal disorders | 0/14 | 2/8 |
| Alanine aminotransferase abnormalInvestigations | 3/14 | 0/8 |
| RashSkin and subcutaneous tissue disorders | 3/14 | 0/8 |
| PhotophobiaEye disorders | 2/14 | 1/8 |
| HypothermiaGeneral disorders | 2/14 | 1/8 |
| PyrexiaGeneral disorders | 2/14 | 1/8 |
| Gamma-glutamyltransferase abnormalInvestigations | 2/14 | 0/8 |
| HypokalaemiaMetabolism and nutrition disorders | 2/14 | 0/8 |
| HypertensionVascular disorders | 2/14 | 0/8 |
| HypothrombinaemiaBlood and lymphatic system disorders | 0/14 | 1/8 |
Safety population: all participants who received at least 1 dose of study medication.
| Age, Continuous(years) | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years | Total |
|---|---|---|---|
| Mean | 6.8 ± 2.9 | 14.4 ± 1.7 | 9.5 ± 4.5 |
| Sex: Female, Male(Participants) | Voriconazole: 2 to <12 Years | Voriconazole: 12 to <18 Years | Total |
|---|---|---|---|
| Female | 8 | 6 | 14 |
| Male | 6 | 2 | 8 |
The record gives a start of Oct 2010, a primary completion of May 2013 and a completion of Jun 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Aug 2015, 2 years 3 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in May 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Voriconazole